Rep. Jefferson Shreve Sells Off Shares of Agilent Technologies, Inc. (NYSE:A)

Representative Jefferson Shreve (R-Indiana) recently sold shares of Agilent Technologies, Inc. (NYSE:A). In a filing disclosed on April 11th, the Representative disclosed that they had sold between $15,001 and $50,000 in Agilent Technologies stock on March 13th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 3/31/2025.
• Purchased $50,001 – $100,000 in shares of Block (NYSE:XYZ) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of DuPont de Nemours (NYSE:DD) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of United Community Banks (NASDAQ:UCB) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of IDEX (NYSE:IEX) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of HNI (NYSE:HNI) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of ServiceNow (NYSE:NOW) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Coinbase Global (NASDAQ:COIN) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Constellation Energy (NASDAQ:CEG) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of Simon Property Group (NYSE:SPG) on 3/31/2025.

Agilent Technologies Stock Performance

NYSE A opened at $103.06 on Wednesday. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $155.35. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The company’s 50-day simple moving average is $122.01 and its 200 day simple moving average is $133.33. The stock has a market cap of $29.38 billion, a P/E ratio of 23.69, a PEG ratio of 2.96 and a beta of 1.19.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.27 by $0.04. The company had revenue of $1.68 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. As a group, research analysts forecast that Agilent Technologies, Inc. will post 5.55 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be issued a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies’s payout ratio is 22.76%.

Institutional Trading of Agilent Technologies

Hedge funds have recently bought and sold shares of the stock. Flynn Zito Capital Management LLC grew its stake in shares of Agilent Technologies by 3.8% during the 4th quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company’s stock worth $251,000 after acquiring an additional 69 shares in the last quarter. IFP Advisors Inc lifted its position in Agilent Technologies by 17.7% during the 4th quarter. IFP Advisors Inc now owns 458 shares of the medical research company’s stock worth $62,000 after buying an additional 69 shares in the last quarter. Tiemann Investment Advisors LLC boosted its stake in shares of Agilent Technologies by 5.6% during the 4th quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company’s stock worth $191,000 after buying an additional 75 shares during the last quarter. Rothschild Investment LLC increased its position in shares of Agilent Technologies by 19.2% in the fourth quarter. Rothschild Investment LLC now owns 491 shares of the medical research company’s stock valued at $66,000 after acquiring an additional 79 shares during the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in Agilent Technologies by 1.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 7,479 shares of the medical research company’s stock worth $1,025,000 after acquiring an additional 87 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Robert W. Baird dropped their target price on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Citigroup raised their price target on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday, December 19th. TD Cowen increased their price objective on Agilent Technologies to $135.00 and gave the company a “buy” rating in a research report on Thursday, April 10th. Finally, Barclays cut their price target on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $146.25.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now owns 35,737 shares in the company, valued at $4,161,931.02. This represents a 4.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Padraig Mcdonnell sold 1,911 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,638 shares of company stock valued at $731,229.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.